Atara Biotherapeutics (ATRA) Stake Increased by California State Teachers Retirement System

California State Teachers Retirement System grew its stake in Atara Biotherapeutics (NASDAQ:ATRA) by 4.6% in the fourth quarter, Holdings Channel reports. The fund owned 42,159 shares of the biotechnology company’s stock after acquiring an additional 1,836 shares during the period. California State Teachers Retirement System’s holdings in Atara Biotherapeutics were worth $763,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in ATRA. Alps Advisors Inc. grew its position in shares of Atara Biotherapeutics by 12.7% in the 4th quarter. Alps Advisors Inc. now owns 33,904 shares of the biotechnology company’s stock valued at $614,000 after purchasing an additional 3,809 shares during the period. Geode Capital Management LLC grew its position in shares of Atara Biotherapeutics by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 196,841 shares of the biotechnology company’s stock valued at $3,562,000 after purchasing an additional 4,731 shares during the period. Bank of New York Mellon Corp grew its position in shares of Atara Biotherapeutics by 4.4% in the 4th quarter. Bank of New York Mellon Corp now owns 129,237 shares of the biotechnology company’s stock valued at $2,339,000 after purchasing an additional 5,415 shares during the period. SG Americas Securities LLC acquired a new position in shares of Atara Biotherapeutics in the 3rd quarter valued at approximately $142,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of Atara Biotherapeutics in the 3rd quarter valued at approximately $170,000. 76.88% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

In other Atara Biotherapeutics news, EVP Heather D. Turner sold 12,214 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $38.01, for a total transaction of $464,254.14. Following the completion of the transaction, the executive vice president now owns 77,112 shares of the company’s stock, valued at approximately $2,931,027.12. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Mitchall G. Clark sold 22,400 shares of the company’s stock in a transaction that occurred on Thursday, March 29th. The stock was sold at an average price of $40.07, for a total value of $897,568.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 315,324 shares of company stock valued at $11,379,838. Insiders own 16.20% of the company’s stock.

NASDAQ:ATRA opened at $35.15 on Friday. Atara Biotherapeutics has a twelve month low of $11.80 and a twelve month high of $49.90. The company has a market cap of $1,415.20, a price-to-earnings ratio of -8.79 and a beta of 2.55.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($1.15) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.15). sell-side analysts expect that Atara Biotherapeutics will post -3.62 earnings per share for the current year.

Several brokerages recently issued reports on ATRA. William Blair reiterated a “buy” rating on shares of Atara Biotherapeutics in a research report on Friday. BidaskClub lowered Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. ValuEngine upgraded Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Guggenheim began coverage on Atara Biotherapeutics in a research report on Thursday, March 15th. They issued a “neutral” rating for the company. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $70.00 price objective on shares of Atara Biotherapeutics in a research report on Tuesday, March 13th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $33.80.

COPYRIGHT VIOLATION NOTICE: “Atara Biotherapeutics (ATRA) Stake Increased by California State Teachers Retirement System” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/08/atara-biotherapeutics-atra-stake-increased-by-california-state-teachers-retirement-system.html.

Atara Biotherapeutics Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics (NASDAQ:ATRA).

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply